These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 18752076)
1. [Up-date on the treatment of serious fungal infections]. Borges Sa M Rev Esp Quimioter; 2008; 21 Spec No 1():14-25. PubMed ID: 18752076 [TBL] [Abstract][Full Text] [Related]
2. Antifungal treatment strategies in high risk patients. Rüping MJ; Vehreschild JJ; Cornely OA Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331 [TBL] [Abstract][Full Text] [Related]
3. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Maertens J Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370 [TBL] [Abstract][Full Text] [Related]
4. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448 [TBL] [Abstract][Full Text] [Related]
5. Invasive fungal infections in the intensive care unit. Vazquez JA Semin Respir Crit Care Med; 2010 Feb; 31(1):79-86. PubMed ID: 20101550 [TBL] [Abstract][Full Text] [Related]
6. The place for itraconazole in treatment. Maertens J; Boogaerts M J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i33-i38. PubMed ID: 16120632 [TBL] [Abstract][Full Text] [Related]
7. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies. Murali S; Langston A Transpl Infect Dis; 2009 Dec; 11(6):480-90. PubMed ID: 19725908 [TBL] [Abstract][Full Text] [Related]
8. Invasive fungal infections in liver transplantation. Liu X; Ling Z; Li L; Ruan B Int J Infect Dis; 2011 May; 15(5):e298-304. PubMed ID: 21345708 [TBL] [Abstract][Full Text] [Related]
9. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Leather HL; Wingard JR Blood Rev; 2006 Sep; 20(5):267-87. PubMed ID: 16781028 [TBL] [Abstract][Full Text] [Related]
10. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients? Salavert M Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S149-53. PubMed ID: 19013340 [TBL] [Abstract][Full Text] [Related]
11. Prevention of fungal infections in the immunocompromised host. Mahfouz T; Anaissie E Curr Opin Investig Drugs; 2003 Aug; 4(8):974-90. PubMed ID: 14508882 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Cornely OA; Aversa F; Cook P; Jones B; Michallet M; Shea T; Vallejo C Eur J Haematol; 2011 Oct; 87(4):289-301. PubMed ID: 21752098 [TBL] [Abstract][Full Text] [Related]
13. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. Chamilos G; Kontoyiannis DP Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387 [TBL] [Abstract][Full Text] [Related]